Has Lorena Lewy-Alterbaum, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,122,103 in general payments to Lorena Lewy-Alterbaum, MD across 1,079 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lorena Lewy-Alterbaum, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lorena Lewy-Alterbaum, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lorena Lewy-Alterbaum, MD

Endocrinology, Diabetes & Metabolism · Hollywood, FLNPI 1184789943

Payments from drug & device makers

$3,122,103in general payments, 2019–2025

Across 1,079 payments — averaging $2893.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$1.6M
AbbVie$706K
Applied Therapeutics, Inc.$243K
AstraZeneca$186K
Braintree Laboratories, Inc.$164K
Sanofi US Services Inc.$86K
plus $156K from 41 others

$13,108in research payments, 2019–2025

Across 8 payments — averaging $1638.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$13K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	79	$1,581,799
AbbVie(2 entities)	216	$706,002
Applied Therapeutics, Inc.	61	$243,066
AstraZeneca	12	$185,540
Braintree Laboratories, Inc.	85	$163,902
Sanofi US Services Inc.	14	$86,178
Novartis	20	$55,992
Akebia Therapeutics Inc	38	$41,194
Pfizer	10	$20,133
Novo Nordisk AS	6	$19,754
Kowa Research Institute, Inc.	4	$8,094
Novo Nordisk	111	$1,826
Lilly USA, LLC	104	$1,439
Sanofi-aventis U.S. LLC	32	$1,057
Boehringer Ingelheim	34	$742
Insulet Corporation	40	$732
Amgen(2 entities)	25	$591
Tandem Diabetes Care, Inc.	11	$466
Xeris Pharmaceuticals, Inc.	23	$461
Amneal Pharmaceuticals LLC	19	$359
IBSA Pharma Inc.	24	$254
Merck	17	$251
Abbott	11	$206
Corcept Therapeutics	8	$196
Radius Health, Inc.	8	$173
Cequr Corporation	4	$161
Astellas Pharma US Inc	7	$153
Sequel Med Tech, LLC	6	$143
Recordati_rare_diseases_inc.	3	$138
Dexcom, Inc.	6	$134
Medtronic	6	$133
Mannkind Corporation	4	$112
Bayer	6	$111
BETA Bionics, Inc.	5	$108
Madrigal Pharmaceuticals	3	$86
Verity Pharmaceuticals Inc.	3	$72
Shire North American Group Inc	1	$71
Ipsen Biopharmaceuticals, Inc	1	$50
Endo Pharmaceuticals Inc.	2	$37
Rhythm Pharmaceuticals, Inc.	1	$33
Johnson & Johnson	2	$30
Ascend Therapeutics US, LLC	2	$28
Antares Pharma, Inc.	1	$25
Ascendis Pharma Endocrinology Inc	1	$23
Senseonics, Incorporated	1	$17
Alfasigma USA, Inc.	1	$15
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$13

How this compares

$3,122,103 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024

$99,676

Medicare patients

217

Services billed

854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Hollywood

Sam LermanHollywood$1.8M
Paul JellingerHollywood$159K
Richard PratleyOrlando$9.2M
Jose MandryOcoee$9.1M
Steven SmithOrlando$7.9M
Barry HorowitzWest Palm Beach$7.1M
Tina ThethiOrlando$3.8M
David SuttonJacksonville$3.1M
Mae Sheikh AliJacksonville$2.9M
James MageeJacksonville$2.7M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →